- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00433914
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
March 5, 2015 updated by: Novartis Vaccines
A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old
To explore safety, Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7LJ
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 8 months (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy 6-8 months old infants
Exclusion Criteria:
- previous receipt of any meningococcal B vaccine;
- previous ascertained or suspected disease caused by N meningitidis;
- history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;
- any present or suspected serious acute or chronic disease
- known or suspected autoimmune disease or impairment /alteration of immune function
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rMenB
6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
|
One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Other Names:
|
Experimental: rMenB+OMV
6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
|
One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Bactericidal Titers ≥1:4 Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: Baseline and one month after second and third vaccination
|
Immunogenicity was measured as the percentage of subjects who achieved bactericidal titers ≥1:4 against meningococcal strains 44/76-SL, 5/99, NZ98/254 (major strains), UK P1.7-2,4, GB101, GB355 and GB364 (additional strains), evaluated using serum bactericidal assay, before vaccination (baseline) and one month after second vaccination (2 months later after vaccination at 6-8 months of age) and third vaccination (at 12 months of age).
|
Baseline and one month after second and third vaccination
|
Percentage of Subjects With Bactericidal Titers ≥1:8 Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: Baseline and one month after second and third vaccination
|
Immunogenicity was measured as the percentage of subjects who achieved bactericidal titers ≥1:8 against meningococcal strains 44/76-SL, 5/99, NZ98/254 (major strains), UK P1.7-2,4, GB101, GB355 and GB364 (additional strains), before vaccination (baseline) and one month after second vaccination (2 months after vaccination at 6-8 months) and third vaccination (at 12 months of age).
|
Baseline and one month after second and third vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Four-fold Rise in Bactericidal Titers Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: One month after second and third vaccination
|
Immunogenicity was measured as the percentage of subjects who achieved a four-fold increase in bactericidal titers against meningococcal strains 44/76-SL, 5/99, NZ98/254 (major strains), UK P1.7-2,4, GB101, GB355 and GB364 (additional strains), one month after second vaccination (2 months after vaccination at 6-8 months) and third vaccination (at 12 months of age).
|
One month after second and third vaccination
|
Geometric Mean Bactericidal Titers Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: Baseline and one month after second and third vaccination
|
The immune response was measured as the geometric mean bactericidal titers directed against meningococcal strains 44/76-SL, 5/99, NZ98/254 (major strains), UK P1.7-2,4, GB101, GB355 and GB364 (additional strains), before vaccination (baseline) and one month after second vaccination (2 months after vaccination at 6-8 months) and third vaccination (at 12 months of age).
|
Baseline and one month after second and third vaccination
|
Geometric Mean ELISA Concentration Against Meningococcal 287-953 Antigen One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: Baseline and one month after second and third vaccination
|
The immune response was measured as the geometric mean concentrations (GMCs) against the meningococcal antigen 287-953, evaluated using enzyme-linked immunosorbent assay (ELISA), before vaccination (baseline) and one month after second vaccination (2 months after vaccination at 6-8 months) and third vaccination (at 12 months of age).
|
Baseline and one month after second and third vaccination
|
Percentage of Subjects With Four-fold Rise in ELISA Concentration Against Meningococcal 287-953 Antigen One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: One month after second and third vaccination
|
Immunogenicity was measured as the percentage of subjects who achieved a four-fold increase in ELISA geometric mean concentrations against meningococcal 287-953 antigen, one month after second vaccination (2 months after vaccination at 6-8 months) and third vaccination (at 12 months of age).
|
One month after second and third vaccination
|
Number of Subjects Who Reported Solicited Local and Systemic Reactions After Each Vaccination of rMenB Vaccine With and Without OMV-NZ
Time Frame: Day 1 through day 7 after each vaccination
|
Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after each vaccination of rMenB vaccine with and without OMV-NZ administered at 6-8 months (vaccination 1), 2 months later (vaccination 2) and at 12 months (vaccination 3).
|
Day 1 through day 7 after each vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Novartis Vaccines (formerly Chiron Vaccines) Novartis, Novartis Vaccines
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Viviani V, Biolchi A, Pizza M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev Vaccines. 2022 May;21(5):645-658. doi: 10.1080/14760584.2022.2050697. Epub 2022 Mar 14.
- Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010 Nov;29(11):e71-9. doi: 10.1097/INF.0b013e3181f59f6d.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
February 9, 2007
First Submitted That Met QC Criteria
February 9, 2007
First Posted (Estimate)
February 12, 2007
Study Record Updates
Last Update Posted (Estimate)
March 6, 2015
Last Update Submitted That Met QC Criteria
March 5, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V72P9
- Eudract Number: 2006-005589-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Disease
-
PfizerCompletedMeningococcal B DiseaseAustralia, Poland, Finland, Czechia
-
PfizerCompleted
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
University of OxfordGlaxoSmithKline; Oxford University Hospitals NHS TrustCompletedInvasive Meningococcal DiseaseUnited Kingdom
-
University of OxfordNorwegian Institute of Public Health; Wellcome TrustCompletedSerogroup B Meningococcal DiseaseUnited Kingdom
-
Serum Institute of India Pvt. Ltd.Completed
-
Novartis VaccinesNovartisCompletedPrevention of Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedPrevention of Meningococcal DiseaseUnited States
-
Canadian Paediatric SocietyGlaxoSmithKline; PfizerRecruitingInvasive Meningococcal DiseaseCanada
-
Canadian Immunization Research NetworkUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
Clinical Trials on rMenB
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisSpain, Brazil, Hungary, Peru
-
Novartis VaccinesCompletedMeningococcal DiseaseAustria, Finland, Germany, Italy, Czech Republic
-
Novartis VaccinesGlaxoSmithKlineCompletedMeningococcal Disease | Meningococcal MeningitisBelgium, Czechia, Germany, Italy, Spain, United Kingdom
-
GlaxoSmithKlineNot yet recruitingMeningitis, MeningococcalKorea, Republic of
-
NovartisNovartis VaccinesCompletedMeningococcal DiseaseItaly, Poland, Russian Federation, Spain, United Kingdom
-
Novartis VaccinesGlaxoSmithKlineCompleted
-
Novartis VaccinesCompletedMeningococcal DiseaseFinland, Czech Republic
-
Novartis VaccinesGlaxoSmithKlineCompletedSerogroup B Meningococcal MeningitisAustria, Czechia, Finland, Germany, Italy
-
GlaxoSmithKlineCompletedInfections, MeningococcalChile, Canada, Australia